Canada Kidney Cancer Therapeutics Market Report 2023 to 2030

Canada Kidney Cancer Therapeutics Market Analysis

$ 3999

The Canada Kidney Cancer Therapeutics Market was valued at $503.20 Mn in 2023 and is predicted to grow at a CAGR of 4.86% from 2023 to 2030, to $701.47 Mn by 2030. The key drivers of this industry include the rising incidence of kidney cancer, advancements in treatment options, and government support. The industry is primarily dominated by players such as AstraZeneca, Pfizer, Novartis, Bristol Myers Squibb, Merck, Bayer, Amgen, Roche, Abbott and Eisai Limited.

ID: IN10CAPH350 CATEGORY: Pharmaceuticals GEOGRAPHY: Canada AUTHOR: Aashwi Mehta

Buy Now

Canada Kidney Cancer Therapeutics Market Executive Summary

The Canada Kidney Cancer Therapeutics Market was valued at $503.20 Mn in 2023 and is predicted to grow at a CAGR of 4.86% from 2023 to 2030, to $701.47 Mn by 2030.

Kidney cancer refers to the abnormal proliferation of cells in the kidney tissue. A tumor is a mass that develops from these cells over time. Hematuria, a lump or mass in the kidney area, fatigue, anemia, loss of appetite, and flank pain are some of the symptoms. Renal Cell Carcinoma (RCC) is the most common type of kidney cancer. Other types include transitional cell carcinoma, Wilms tumor, and renal sarcoma. Several risk factors contributing to kidney cancer can be further divided into modifiable and non-modifiable factors. Smoking and Obesity are the two major modifiable factors responsible for kidney disease, whereas age and gender are the non-modifiable ones.

In 2024, it is projected that 9,000 Canadians will be diagnosed with kidney and renal pelvis cancer, and 1,950 will die from the disease. Among these, 5,900 men are expected to be diagnosed, with 1,250 fatalities, while 3,100 women will be diagnosed, with 670 succumbing to the illness. This data highlights the significant impact of kidney and renal pelvis cancer on both men and women in Canada. The market is driven by significant factors like the rising incidence of kidney cancer, advancements in treatment options, and government support. However, stringent regulatory processes, higher costs, and side effects related to treatment restrict the growth and potential of the market.

Prominent players in this field include AstraZeneca, Pfizer, Novartis, Bristol Myers Squibb, Merck, Bayer, Amgen, Roche, Abbott and Eisai Limited.

Market Dynamics

Market Growth Drivers

Rising incidence of Kidney cancer: The estimated 1,950 kidney and renal pelvis cancer-related deaths in 2024, together with the 9,000 kidney and renal pelvis cancer diagnoses predicted for Canada by the Canadian Cancer Society, point to a serious healthcare crisis and underline the pressing need for efficient therapies. As new and better treatments are sought to meet this urgent medical need, Canada's renal cancer therapeutics market is expected to rise significantly due to the high incidence and mortality rate, which drives demand for advanced renal cancer therapeutics.

Advancements in treatment options: The introduction of targeted treatments, ablation therapy, and immunotherapies, among other recent developments in the Canadian kidney cancer therapeutic market, is greatly expanding the range of available treatment options and improving patient outcomes. Because of these developments, there is a greater need for advanced therapies, which propels the market, providing pharmaceutical companies with a great chance of meeting the increasing need for indicated therapies.

Government support: Cancer patients' financial burden is considerably lessened by government support programs in Canada, such as tax deductions, employment insurance, and the Canada Pension Plan. Furthermore, Kidney Cancer Canada provides patients, caregivers, and medical professionals with essential advocacy, information, and support. By ensuring that patients can afford and pursue innovative medicines, these measures collectively improve patient access to care and treatment alternatives, stimulating demand in the renal cancer therapeutic market and promoting innovation and market growth.

Market Restraints

Stringent Regulatory Process: The Therapeutic Products Directorate (TPD) of Health Canada oversees the regulation of pharmaceuticals and medical devices in Canada, and it is a rigorous and lengthy licensing procedure. Drug registration is particularly difficult since it involves thorough evaluations of safety and efficacy data as well as several application submissions. As a result, the lengthy approval procedure postpones the release of novel medicines for kidney cancer, greatly hindering the timely introduction of novel treatments and impeding market expansion in Canada.

High Cost of Treatment: Even with Canada's universal healthcare system, those who are diagnosed with cancer must pay a substantial portion of their treatment out of pocket—an average of $290 a month as of 2023. Exorbitant personal expenses may make it difficult for patients to get essential care, which may lower demand for innovative renal cancer therapies overall and hinder market expansion.

Side Effects of Treatment: Side effects from kidney cancer treatments represent a major market restraint. These negative effects may limit the use of specific therapies and decrease patient compliance, which may affect the overall efficacy of those therapies. Renal cancer therapeutic market growth and innovation are hampered by patients' and healthcare providers' reluctance to embrace novel treatments due to the possibility of severe adverse effects.

Regulatory Landscape and Reimbursement Scenario

The Ministry of Health is in charge of directing healthcare services and policy in Canada, as well as allocating funds and maintaining national health standards. Health Canada oversees the safety and effectiveness of all health products, including food and pharmaceuticals, while the Canadian Institutes of Health Research (CIHR) provides funding for health research and innovation nationwide, promoting scientific breakthroughs and evidence-based treatments. Health Canada-approved cancer medications are legal for sale in the nation, but provincial and territory payors may not always cover their expenses. These medications need to go through a Health Technology Assessment (HTA) by the pan-Canadian Oncology Drug Review (pCODR) of CADTH (Canadian Agency for Drugs and Technologies in Health) to be funded by the public. Provinces and territories determine reimbursement on an individual basis following approval.

Competitive Landscape

Key Players

Here are some of the major key players in the Canada Kidney Cancer Therapeutic Market:

AstraZeneca
Pfizer
Novartis
Bristol Myers Squibb
Merck
Bayer
Amgen
Roche
Abbott
Eisai Limited

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Canada Kidney Cancer Therapeutics Market Segmentation

By Cancer Type

Wilms tumor
Clear Cell Renal Carcinoma
Transitional Cell Carcinoma
Others

By Treatment

Targeted Therapy
Immunotherapy
Radiation Therapy
Surgeries

By End Users

Hospitals
Specialty Centers
Ambulatory Surgical Centers

By Distribution Channel

Hospital-based pharmacies
Retail pharmacies
Online pharmacies

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.